What is Centogene?
Centogene N.V. operates as a global provider of pharmaceutical solutions and diagnostic tests, with a strong presence across Europe, the Middle East, North America, Latin America, and the Asia Pacific. The company specializes in delivering data-driven insights for rare and neurodegenerative diseases, serving patients, physicians, and pharmaceutical companies. Its offerings include the CENTOGENE MOx 2.0 multiomic solution, the CentoCloud SaaS platform for genomic variant analysis, and the NEW CentoGenome assay, all designed to accelerate access to potential treatment options for complex genetic conditions. This focus positions Centogene at the forefront of precision medicine and rare disease diagnostics.
How much funding has Centogene raised?
Centogene has raised a total of $146M across 4 funding rounds:
Series A
$28M
Stock Offering
$56M
Share Placement
$17M
Debt
$45M
Series A (2017): $28M with participation from Careventures, TVM Capital, and Deutsche Private Equity
Stock Issuance/Offering (2019): $56M led by Undisclosed
Share Placement (2022): $17M supported by TVM Capital, Careventures, and Deutsche Private Equity
Debt (2022): $45M featuring Oxford Finance
Key Investors in Centogene
TVM Capital
TVM Capital Life Science is a transatlantic venture capital firm focused on investing in innovative life science products and companies. They provide capital and expertise to support the development of breakthrough therapies and medical products that aim to transform healthcare.
Careventures
Careventures is an independent pan-European private equity firm dedicated to improving healthcare through smart investments. The company partners with middle-market healthcare companies and entrepreneurs to help them transform their ideas into leading international firms.
Deutsche Private Equity
DPE Deutsche Private Equity is an independent German investment firm. DPE focuses on mid-sized companies in the German-speaking region that operate in industries providing long-term growth prospects.
What's next for Centogene?
The recent major strategic investment in Centogene indicates a phase of accelerated scaling and potential expansion of its diagnostic and pharmaceutical solution offerings. This infusion of capital is likely to fuel further research and development into novel treatments for rare and neurodegenerative diseases, as well as enhance its data analytics capabilities through platforms like CentoCloud. The company's strategic focus on leveraging multiomic data suggests a commitment to deepening its impact in precision medicine, potentially leading to new partnerships and market penetration in key geographical regions. Centogene's trajectory points towards solidifying its role as a leader in the specialized field of genetic diagnostics and therapeutic development.
See full Centogene company page
